Labetuzumab

Identification

Generic Name
Labetuzumab
DrugBank Accession Number
DB05097
Background

Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Structure
Db05097
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • hMN-14
  • Labetuzumab
  • MAb hMN14
  • Monoclonal antibody hMN-14
External IDs
  • IMMU-100

Pharmacology

Indication

Labetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action

labetuzumab could significantly increase the chemosensitivity of human colon and breast cancer cells in vitro to several anticancer drugs.

TargetActionsOrganism
UCarcinoembryonic antigen-related cell adhesion molecule 5
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Labetuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Labetuzumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Labetuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Alirocumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Labetuzumab is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Labetuzumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Asfotase alfa.
AtezolizumabThe risk or severity of adverse effects can be increased when Labetuzumab is combined with Atezolizumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
CEA-Cide

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
EFE6X5M3UY
CAS number
219649-07-7

References

General References
  1. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, Ghadimi BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM: Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005 Sep 20;23(27):6763-70. [PubMed:16170184]
  2. Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM: Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007 Sep;14(9):2577-90. Epub 2007 Jun 15. [PubMed:17570017]
PubChem Substance
347909944
Wikipedia
Labetuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2WithdrawnTreatmentMetastatic Colorectal Cancer (MCRC)1
1TerminatedTreatmentNeoplasms, Colorectal1
1, 2CompletedTreatmentBreast Cancer / Carcinoma, Colorectal / Colorectal Cancers / Malignant Neoplasm of Colon / Neoplasms, Breast / Neoplasms, Colorectal / Rectal Carcinoma1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Malignant Neoplasm of Colon / Neoplasms, Colorectal / Rectal Carcinoma1
1, 2CompletedTreatmentNeoplasms, Pancreatic1
1, 2RecruitingDiagnosticCarcinoma NOS / Colorectal Cancers / Gastrointestinal Cancers / Neoplasms / Peritoneal Carcinomatosis1
1, 2WithdrawnTreatmentMalignant Neoplasm of Colon / Metastatic Colorectal Cancer (MCRC) / Rectal Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein homodimerization activity
Specific Function
Cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. Receptor for E.coli Dr adhesins.
Gene Name
CEACAM5
Uniprot ID
P06731
Uniprot Name
Carcinoembryonic antigen-related cell adhesion molecule 5
Molecular Weight
76794.015 Da
References
  1. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM: CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009 Oct 1;15(19):6052-61. doi: 10.1158/1078-0432.CCR-09-0586. Epub 2009 Sep 29. [PubMed:19789330]

Drug created on October 21, 2007 22:23 / Updated on February 21, 2021 18:51